New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:48 EDTMYGN, LHMyriad cancer testing franchise to lose share, says Leerink
Leerink says Horizon Blue Cross Blue Shield's announcement that it is terminating its participation agreements with Myriad Genetics is consistent with its view that the company's core hereditary cancer testing franchise will experience market share and price erosion over time. Leerink notes defenders of Myriad had argued that the company remained in Horizon's network while LabCorp (LH) was the preferred provider, which will no longer be the case. It has a Market Perform rating on Myriad.
News For MYGN;LH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
10:44 EDTMYGNCMS may have made mistake with Myriad BRCA pricing, says Piper Jaffray
Piper Jaffray analyst William Quirk noted that the Centers for Medicare and Medicaid Services, or CMS, released the final 2016 Clinical Diagnostic Laboratory Fee Schedule yesterday, which showed Myriad Genetics' BRCA1/2 sequencing and full duplication/deletion analysis priced at $1,839.54, down from the $2,483.37 listed in the preliminary and final CLFS determination documents. Quirk said this may be an error and that he anticipates CMS to issue a correction and/or Myriad to file an appeal in the near-term. The analyst keeps an Overweight rating on Myriad shares.
November 23, 2015
05:36 EDTMYGNGenomic Health upgraded to Buy from Neutral at UBS
Subscribe for More Information
November 19, 2015
16:27 EDTLHGlenview Capital Management reports 5.29% passive stake in LabCorp
Subscribe for More Information
07:19 EDTMYGNCMS decision a big positive for Myriad Genetics, says Stephens
Subscribe for More Information
November 18, 2015
09:49 EDTMYGNCMS reversal removes 'huge overhang' for CareDx, says Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use